AU2013204313C1 - Combination Therapy - Google Patents

Combination Therapy Download PDF

Info

Publication number
AU2013204313C1
AU2013204313C1 AU2013204313A AU2013204313A AU2013204313C1 AU 2013204313 C1 AU2013204313 C1 AU 2013204313C1 AU 2013204313 A AU2013204313 A AU 2013204313A AU 2013204313 A AU2013204313 A AU 2013204313A AU 2013204313 C1 AU2013204313 C1 AU 2013204313C1
Authority
AU
Australia
Prior art keywords
optionally substituted
aryl
alkyl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013204313A
Other languages
English (en)
Other versions
AU2013204313B2 (en
AU2013204313A1 (en
Inventor
Daniel J. Inglis
Gabriel Kremmidiotis
Tina C. Lavranos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902291A external-priority patent/AU2012902291A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Priority to AU2013204313A priority Critical patent/AU2013204313C1/en
Publication of AU2013204313A1 publication Critical patent/AU2013204313A1/en
Publication of AU2013204313B2 publication Critical patent/AU2013204313B2/en
Priority to AU2015264805A priority patent/AU2015264805B2/en
Application granted granted Critical
Publication of AU2013204313C1 publication Critical patent/AU2013204313C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013204313A 2012-06-01 2013-04-12 Combination Therapy Ceased AU2013204313C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013204313A AU2013204313C1 (en) 2012-06-01 2013-04-12 Combination Therapy
AU2015264805A AU2015264805B2 (en) 2012-06-01 2015-12-01 Combination Therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902291A AU2012902291A0 (en) 2012-06-01 Combination Therapy
AU2012902291 2012-06-01
AU2013204313A AU2013204313C1 (en) 2012-06-01 2013-04-12 Combination Therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015264805A Division AU2015264805B2 (en) 2012-06-01 2015-12-01 Combination Therapy

Publications (3)

Publication Number Publication Date
AU2013204313A1 AU2013204313A1 (en) 2013-12-19
AU2013204313B2 AU2013204313B2 (en) 2015-09-03
AU2013204313C1 true AU2013204313C1 (en) 2016-04-07

Family

ID=49672192

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013204313A Ceased AU2013204313C1 (en) 2012-06-01 2013-04-12 Combination Therapy
AU2013270425A Abandoned AU2013270425A1 (en) 2012-06-01 2013-06-03 Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2013270425A Abandoned AU2013270425A1 (en) 2012-06-01 2013-06-03 Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia

Country Status (9)

Country Link
US (1) US20150133401A1 (https=)
EP (1) EP2854796B1 (https=)
JP (1) JP6005855B2 (https=)
CN (1) CN104703595B (https=)
AU (2) AU2013204313C1 (https=)
CA (1) CA2874778A1 (https=)
IL (1) IL235927A (https=)
NZ (1) NZ630465A (https=)
WO (1) WO2013177633A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016228116A1 (en) * 2015-03-05 2017-09-14 Bionomics Limited Combination treatment protocol
SG11201707128TA (en) * 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
JP2020534289A (ja) * 2017-09-14 2020-11-26 ランケナー インスティテュート フォー メディカル リサーチ がんの治療のための方法および組成物
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN110680824A (zh) * 2018-07-05 2020-01-14 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途
CN109675039A (zh) * 2018-12-21 2019-04-26 中国科学院长春应用化学研究所 药物组合、抗肿瘤的药物和应用
CN112755188B (zh) * 2019-11-01 2022-03-08 中国科学院微生物研究所 Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548B (zh) 2021-08-27 2026-03-03 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20250160163A (ko) 2023-02-27 2025-11-11 아센타위츠 파마슈티컬즈 리미티드 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340062A (en) 1992-08-13 1994-08-23 Harmon Industries, Inc. Train control system integrating dynamic and fixed data
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
WO2003070241A1 (en) 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
AU2006212726C1 (en) 2005-02-14 2013-05-16 Bionomics Limited Novel tubulin polymerisation inhibitors
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
JP5315060B2 (ja) * 2006-02-03 2013-10-16 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
CN104043125B (zh) * 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US20110130367A1 (en) * 2009-11-27 2011-06-02 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
WO2011063469A1 (en) * 2009-11-27 2011-06-03 Bionomics Limited Tubulin biomarker assay
CA2686587C (en) * 2009-11-27 2018-01-16 Bionomics Limited Combination therapy for treating proliferative diseases
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer

Also Published As

Publication number Publication date
JP2015518008A (ja) 2015-06-25
CA2874778A1 (en) 2013-12-05
IL235927A0 (en) 2015-01-29
IL235927A (en) 2017-11-30
AU2013204313B2 (en) 2015-09-03
CN104703595A (zh) 2015-06-10
HK1207286A1 (en) 2016-01-29
WO2013177633A1 (en) 2013-12-05
EP2854796B1 (en) 2018-11-14
US20150133401A1 (en) 2015-05-14
NZ630465A (en) 2015-09-25
EP2854796A4 (en) 2015-10-14
JP6005855B2 (ja) 2016-10-12
CN104703595B (zh) 2017-07-28
EP2854796A1 (en) 2015-04-08
AU2013204313A1 (en) 2013-12-19
AU2013270425A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
AU2013204313C1 (en) Combination Therapy
CA2771789C (en) Combination therapy for treating proliferative diseases
US8716335B2 (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
US20140248375A1 (en) Combination Therapy for Treating Proliferative Diseases
AU2014389437B2 (en) Method for treating chronic lymphocytic leukemia
AU2015264805B2 (en) Combination Therapy
WO2024028847A1 (en) Combination therapy for treating cancers
CA2686587C (en) Combination therapy for treating proliferative diseases
HK1172257B (en) Combination therapy for treating proliferative diseases
BR112020009596A2 (pt) combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer
HK1207286B (en) Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer
AU2009240878B2 (en) Combination Therapy for Treating Proliferative Diseases
US20170119727A1 (en) A therapeutic protocol for treating ovarian cancer

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 NOV 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 NOV 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired